Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Capan-1 |
Human pancreatic adenocarcinoma cell line | ATCC HTB-79 | Human | digestive organs | cell line | adherent | plasmid | Metafectene PRO | publication | J. Pahle, Dissertation, 2017, Humboldt-Universität zu Berlin | Link | ||
CD4+ T cells |
Human CD4+ T cells | Human | immune system | suspension | siRNA | RNA-Interference | Metafectene PRO | publication | J.-S. Chung et al., Eur. J. Immunol., 2011,41: 1794–1799, DOI 10.1002/eji.201041233 | ||||
CMel-2 |
Human primary superficial spreading melanoma cells | Human | skin | primary cell | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | I. Venza et al., Int. Immunopharmacol., 2014, 21: 439–446; doi.org/10.1016/j.intimp.2014.05.024 | |||
CMel-2 |
Human primary superficial spreading melanoma cells | Human | skin | primary cell | adherent | plasmid | Metafectene PRO | publication | I. Venza et al., Int. Immunopharmacol., 2014, 21: 439–446; doi.org/10.1016/j.intimp.2014.05.024 | ||||
Colo205 |
Human colon adenocarcinoma cell line | ATCC CCL-222 | Human | digestive organs | cell line | adherent | plasmid | Metafectene PRO | application note | ![]() |
|||
Daoy |
Human desmoplastic cerebellar medulloblastoma cell line | ATCC HTB-186 | Human | brain | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | M.C. Burger et al., Int. J. of Oncology, 2012, 41: 235-241, DOI: 10.3892/ijo.2012.1446 | Link | |
DLD-1 |
Human colon adenocarcinoma cell line | ATCC CCL-221 | Human | digestive organs | cell line | adherent | plasmid | Metafectene PRO | publication | M. Masià-Balagué et al., J. Biol. Chem., Jun 2015; 290: 15197 - 15209 | |||
DU145 |
Human prostate cancer cell line, derived from metastatic site: brain | ATCC HTB-81 | Human | brain | cell line | adherent | plasmid | Metafectene PRO | publication | C. Morich, Dissertation, 2016, Georg-August University Göttingen | Link | ||
EJ138 |
Human bladder carcinoma cell line | ECACC 85061108 | Human | urinary system | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | M.C. Burger et al., Int. J. of Oncology, 2012, 41: 235-241, DOI: 10.3892/ijo.2012.1446 | Link | |
EVLC2 |
Human umbilical vein endothelial cells | Human | vasculature | unknown | adherent | plasmid | Metafectene PRO | application note | ![]() |
||||
Flp-In T-REx HeLa |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | T. M. Nthiga et al., J. Cell Biol., 2021, 220, 6, doi.org/10.1083/jcb.202006128 | Link | ||
Flp-In T-REx HeLa |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | CRISPR | Metafectene PRO | publication | T. M. Nthiga et al., J. Cell Biol., 2021, 220, 6, doi.org/10.1083/jcb.202006128 | Link | ||
Flp-in TREx 293 |
Human embryonic kidney cell line (derivative of HEK293) | Human | urinary system | cell line | adherent | plasmid | CRISPR | Metafectene PRO | publication | T. M. Nthiga et al., The EMBO J., 39: e103649, DOI 10.15252/embj.2019103649 | Link | ||
Flp-in TREx 293 |
Human embryonic kidney cell line (derivative of HEK293) | Human | urinary system | cell line | adherent | plasmid | CRISPR | Metafectene PRO | publication | B.K. Shrestha et al., J Biol Chem., 2020, 295(5): 1240–1260, doi: 10.1074/jbc.RA119.010068 | Link | ||
Flp-in TREx 293 |
Human embryonic kidney cell line (Derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | J. Wright et al., J. Biol. Chem., Oct 2013; 288: 31010 - 31018 | Link | |||
Flp-in TREx 293 |
Human embryonic kidney cell line (derivative of HEK293) | Human | urinary system | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | T. M. Nthiga et al., The EMBO J., 39: e103649, DOI 10.15252/embj.2019103649 | Link | ||
Flp-in TREx 293 |
Human embryonic kidney cell line (Derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | T. Ramming et al., Redox Biology, 2016, 714-20; doi.org/10.1016/j.redox.2015.11.004 | ||||
Flp-in TREx 293 |
Human embryonic kidney cell line (derivative of HEK293) | Human | urinary system | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | B.K. Shrestha et al., J Biol Chem., 2020, 295(5): 1240–1260, doi: 10.1074/jbc.RA119.010068 | Link | ||
Flp-in TREx 293 |
Human embryonic kidney cell line (Derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | T. Ramming, Dissertation, 2014, Universitaet Basel | Link | |||
Flp-in TREx 293 |
Human embryonic kidney cell line (Derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | J. Birk et al., J. Cell Sci., Apr 2013; 126: 1604 - 1617 | Link | |||
Flp-in TREx 293 |
Human embryonic kidney cell line (Derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | J. J. Wright, PhD Thesis, 2015, University of Michigan | Link | |||
Flp-in TREx 293 |
Human embryonic kidney cell line (Derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | CRISPR | Metafectene PRO | publication | B. K. Shrestha et al., J. Biol. Chem., 2019,doi/10.1074/jbc.RA119.010068 | Link | ||
Flp-In TREx HeLa |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | CRISPR | Metafectene PRO | publication | T. M. Nthiga et al., The EMBO J., 39: e103649, DOI 10.15252/embj.2019103649 | Link | ||
Flp-In TREx HeLa |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | N.E. Taboko, Masters Thesis, 2020, UiT Norges arktiske universitet | Link | ||
Flp-In TREx HeLa |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | T. M. Nthiga et al., The EMBO J., 39: e103649, DOI 10.15252/embj.2019103649 | Link |